A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine

PHASE3CompletedINTERVENTIONAL
Enrollment

4,116

Participants

Timeline

Start Date

November 30, 2002

Primary Completion Date

April 30, 2004

Study Completion Date

April 30, 2004

Conditions
DiphtheriaTetanusAcellular Pertussis
Interventions
BIOLOGICAL

Combined diphtheria, tetanus, acellular pertussis vaccine

Trial Locations (44)

2740

GSK Investigational Site, New Bedford

11794

GSK Investigational Site, Stony Brook

14620

GSK Investigational Site, Rochester

15241

GSK Investigational Site, Pittsburgh

18960

GSK Investigational Site, Sellersville

23510

GSK Investigational Site, Norfolk

27514

GSK Investigational Site, Chapel Hill

27710

GSK Investigational Site, Durham

28358

GSK Investigational Site, Lumberton

32209

GSK Investigational Site, Jacksonville

37660

GSK Investigational Site, Kingsport

40004

GSK Investigational Site, Bardstown

44109

GSK Investigational Site, Cleveland

44118

GSK Investigational Site, University Heights

60614

GSK Investigational Site, Chicago

68178

GSK Investigational Site, Omaha

72202

GSK Investigational Site, Little Rock

72401

GSK Investigational Site, Jonesboro

76508

GSK Investigational Site, Temple

77030

GSK Investigational Site, Houston

77802

GSK Investigational Site, Bryan

78626

GSK Investigational Site, Georgetown

80112

GSK Investigational Site, Centennial

80304

GSK Investigational Site, Boulder

80401

GSK Investigational Site, Golden

84084

GSK Investigational Site, West Jordan

84109

GSK Investigational Site, Salt Lake City

85201

GSK Investigational Site, Mesa

85282

GSK Investigational Site, Tempe

90274

GSK Investigational Site, Rolling Hills Est

90277

GSK Investigational Site, Redondo Beach

90502

GSK Investigational Site, Torrance

92021

GSK Investigational Site, Escondido

92835

GSK Investigational Site, Fullerton

92886

GSK Investigational Site, Yorba Linda

06457

GSK Investigational Site, Middletown

06360

GSK Investigational Site, Norwich

02115

GSK Investigational Site, Boston

02130

GSK Investigational Site, Boston

01757

GSK Investigational Site, Milford

01801

GSK Investigational Site, Woburn

08889

GSK Investigational Site, Whitehouse Station

44308-1062

GSK Investigational Site, Akron

15213-2583

GSK Investigational Site, Pittsburgh

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00109330 - A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine | Biotech Hunter | Biotech Hunter